Related Content
- The Little Clinic adds new insurance provider to accepted plans
- Gallup: Take Care Clinics top in customer service
- With health reform outlook dimmed, pharmacy can’t abandon its agenda
- Bartell to cease filling Medicaid prescriptions at 15 locations
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
ARDEE, Ireland The Food and Drug Administration has approved a new contraceptive from Warner Chilcott, the drug maker said Friday.
The company said it plans to launch Lo Loestrin Fe (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets) early next year. The company said the contraceptive contains the lowest dosage of estrogen — 10 micrograms — of any oral contraceptive currently available in the U.S. market.
“We are excited about the approval of Lo Loestrin Fe, which complements our women’s healthcare franchise and expands the product offerings in our branded oral contraceptive portfolio,” president and CEO Roger Boissonneault said in a statement.
